The Efficacy Of Montelukast Sodium And Budesonide On Pulmonary Function In Infantile Asthma

Objective: To analyze the clinical efficacy of montelukast sodium combined with budesonide on the pulmonary function of children with asthma. Methods: A prospective study was carried out on 100 children with asthma who were randomly divided into a control group (50 cases) and an experimental group (50 cases). The control group received budesonide, and the experimental group was given montelukast sodium and budesonide. We compared the two groups' clinical efficacy, their post-treatment clinical symptom scores, their adverse reactions, and their pulmonary function indices (forced expiratory volume in one second (FEV1), peak expiratory flow (PEF), and the percentage of FEV1/forced vital capacity (FEV/FVC)). Results: After the treatment, the FEV1, PEF, and FEV1/FVC as well as the total effective rate in the experimental group were significantly higher than they were in the control group (all P<0.05). After the treatment, the daytime asthma control and the nighttime asthma control scores of the experimental group were significantly lower than they were in the control group (P<0.05). Though the incidence of adverse reactions in the experimental group was lower than it was in the control group, the difference was not statistically significant (P>0.05). In the one year follow up, the recurrence rate in the experimental group was significantly lower than it was in the control group. Conclusion: In children, the combination of montelukast sodium and budesonide can effectively improve the patients' pulmonary function indices, relieve their asthma symptoms, lower their incidence of adverse reactions, and reduce the recurrence rate.